S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This Stock Could Go Up 66% or More. (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This Stock Could Go Up 66% or More. (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This Stock Could Go Up 66% or More. (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This Stock Could Go Up 66% or More. (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
NASDAQ:OPK

OPKO Health (OPK) Stock Forecast, Price & News

$1.62
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$1.60
$1.65
50-Day Range
$1.62
$2.17
52-Week Range
$1.00
$2.24
Volume
3.91 million shs
Average Volume
2.19 million shs
Market Capitalization
$1.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.85

OPKO Health MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
137.7% Upside
$3.85 Price Target
Short Interest
Bearish
8.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$1.82 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.20) to ($0.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

245th out of 965 stocks

Pharmaceutical Preparations Industry

100th out of 454 stocks


OPK stock logo

About OPKO Health (NASDAQ:OPK) Stock

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

OPK Price History

OPK Stock News Headlines

WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
Opko Health (OPK) Receives a Buy from H.C. Wainwright
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Barrington Reaffirms Their Buy Rating on Opko Health (OPK)
Opko Health (OPK) Q2 2023 Earnings Call Transcript
A Preview Of OPKO Health's Earnings
Opko Health (NASDAQ: OPK)
See More Headlines
Receive OPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

OPK Company Calendar

Last Earnings
8/03/2023
Today
9/23/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:OPK
CUSIP
68375N10
Employees
4,196
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.85
High Stock Price Forecast
$5.40
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+137.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-328,400,000.00
Pretax Margin
-30.18%

Debt

Sales & Book Value

Annual Sales
$1.00 billion
Book Value
$2.02 per share

Miscellaneous

Free Float
443,580,000
Market Cap
$1.25 billion
Optionable
Optionable
Beta
1.76
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Phillip Frost Ph.D. (Age 87)
    Chairman & CEO
    Comp: $972.2k
  • Dr. Jane H. Hsiao M.B.A. (Age 76)
    MBA, Ph.D., Vice Chairman & Chief Technical Officer
    Comp: $912.2k
  • Dr. Elias Adam Zerhouni M.D. (Age 72)
    Pres & Vice Chairman
    Comp: $1.41M
  • Mr. Adam E. Logal (Age 45)
    Sr. VP, CFO, Chief Accounting Officer & Treasurer
    Comp: $712.2k
  • Mr. Steven D. Rubin Esq. (Age 63)
    J.D., Exec. VP of Admin. & Director
    Comp: $822.2k
  • Dr. Akhtar Ashfaq
    Sr. VP of Clinical R&D and Medical Affairs
  • Ms. Jane Pine Wood Esq. (Age 61)
    J.D., Chief Legal Officer of Bio-Reference Laboratories
  • Dr. Gary J. Nabel M.D. (Age 69)
    Ph.D., Chief Innovation Officer & Director
  • Dr. David Okrongly Ph.D. (Age 64)
    Pres of OPKO Diagnostics
  • Dr. Charles W. Bishop (Age 71)
    Chief Exec. Officer of OPKO Renal













OPK Stock - Frequently Asked Questions

Should I buy or sell OPKO Health stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPK shares.
View OPK analyst ratings
or view top-rated stocks.

What is OPKO Health's stock price forecast for 2023?

2 Wall Street analysts have issued twelve-month price targets for OPKO Health's shares. Their OPK share price forecasts range from $2.00 to $5.40. On average, they anticipate the company's share price to reach $3.85 in the next twelve months. This suggests a possible upside of 137.7% from the stock's current price.
View analysts price targets for OPK
or view top-rated stocks among Wall Street analysts.

How have OPK shares performed in 2023?

OPKO Health's stock was trading at $1.25 at the start of the year. Since then, OPK shares have increased by 29.6% and is now trading at $1.62.
View the best growth stocks for 2023 here
.

When is OPKO Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our OPK earnings forecast
.

How were OPKO Health's earnings last quarter?

OPKO Health, Inc. (NASDAQ:OPK) issued its quarterly earnings results on Thursday, August, 3rd. The biotechnology company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.04. The biotechnology company had revenue of $265.40 million for the quarter, compared to the consensus estimate of $201.97 million. OPKO Health had a negative trailing twelve-month return on equity of 13.33% and a negative net margin of 24.10%. The company's revenue for the quarter was down 14.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.04) earnings per share.

What ETFs hold OPKO Health's stock?
What is Philip Frost's approval rating as OPKO Health's CEO?

21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OPKO Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

What is OPKO Health's stock symbol?

OPKO Health trades on the NASDAQ under the ticker symbol "OPK."

Who are OPKO Health's major shareholders?

OPKO Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.53%), State Street Corp (1.18%), Geode Capital Management LLC (1.13%), Charles Schwab Investment Management Inc. (0.67%), Northern Trust Corp (0.58%) and Dimensional Fund Advisors LP (0.49%). Insiders that own company stock include Elias A Zerhouni, Gary J Nabel, Jon R Cohen, Opko Health, Inc, Phillip Md Et Al Frost and Robert J Shovlin.
View institutional ownership trends
.

How do I buy shares of OPKO Health?

Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OPKO Health's stock price today?

One share of OPK stock can currently be purchased for approximately $1.62.

How much money does OPKO Health make?

OPKO Health (NASDAQ:OPK) has a market capitalization of $1.25 billion and generates $1.00 billion in revenue each year. The biotechnology company earns $-328,400,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does OPKO Health have?

The company employs 4,196 workers across the globe.

How can I contact OPKO Health?

OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The official website for the company is www.opko.com. The biotechnology company can be reached via phone at (305) 575-4100, via email at mmiller@lhai.com, or via fax at 305-575-6015.

This page (NASDAQ:OPK) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -